Rituximab is a chimeric mouse–human monoclonal antibody (mAb) that targets the B-cell surface marker CD20 with high affinity. CD20 expression spans the developmental stages from the pre-B cell until ...
FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback